Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2020 Jun 2;31(9):107722. doi: 10.1016/j.celrep.2020.107722

Inferring Active Metabolic Pathways from Proteomics and Essentiality Data

Ariadna Montero-Blay 1, Carlos Piñero-Lambea 1, Samuel Miravet-Verde 1, Maria Lluch-Senar 1, Luis Serrano 1,2,3,4,
PMCID: PMC7273199  PMID: 32492430

Summary

Here, we propose an approach to identify active metabolic pathways by integrating gene essentiality analysis and protein abundance. We use two bacterial species (Mycoplasma pneumoniae and Mycoplasma agalactiae) that share a high gene content similarity yet show significant metabolic differences. First, we build detailed metabolic maps of their carbon metabolism, the most striking difference being the absence of two key enzymes for glucose metabolism in M. agalactiae. We then determine carbon sources that allow growth in M. agalactiae, and we introduce glucose-dependent growth to show the functionality of its remaining glycolytic enzymes. By analyzing gene essentiality and performing quantitative proteomics, we can predict the active metabolic pathways connected to carbon metabolism and show significant differences in use and direction of key pathways despite sharing the large majority of genes. Gene essentiality combined with quantitative proteomics and metabolic maps can be used to determine activity and directionality of metabolic pathways.

Keywords: metabolism, bacteria, transposon, active pathways, mycoplasma, proteomics, essentiality

Graphical Abstract

graphic file with name fx1.jpg

Highlights

  • Active metabolic bacterial pathways are identified

  • Integration of gene essentiality and proteomics allow prediction of active pathways

  • Glucose-dependent growth is restored in Mycoplasma agalactiae

  • Two Mycoplasma species show different usage of metabolic pathways


Montero-Blay et al. identify active metabolic pathways in bacteria by integrating gene essentiality data and quantitative proteomics. Predictions agree with experimental information and show substantial differences in usage and directionality of metabolic pathways in bacteria with high degree of gene similarity.

Introduction

Evolution has shaped bacterial metabolism during millions of years, allowing these microorganisms to successfully colonize an enormous variety of environments, hosts, or tissues within a particular host (Rottem, 2003). Aside from its interest from an evolutionary point of view, understanding bacterial metabolism is key for a wide variety of applications. For instance, bacteria are attractive workhorses for the green production of valuable compounds, such as those related with the denim industry, that have been classically produced using environmentally hazardous processes (Hsu et al., 2018). In addition, studying the metabolism of a bacterium is essential to understand its interaction with the bacterium’s host. Specifically, it has recently been shown that the microbiome metabolism can affect dramatically drug pharmacokinetics (Zimmermann et al., 2019), which therefore should be taken into account for personalized medicine purposes. Lastly, a detailed knowledge of all chemical reactions that take place in a particular strain could help to develop attenuated vaccines or bactericidal therapies based on selectively toxic metabolic intermediates.

Understanding metabolism requires being able to build an accurate metabolic map with no dead-end reactions or futile loops. This could be hindered by the fact that some metabolic enzymes can use different substrates and produce different products. For instance, fructose bisphosphate aldolase (Fba) is a key enzyme of the glycolytic pathway that catalyzes the conversion of fructose 1,6-bisphosphate (fructose-1,6BP) to dihydroxyacetone phosphate (DHAP) and glyceraldehyde phosphate (GAP). However, the same enzyme can also perform other less well-known reactions, such as conversion of fructose 1-phosphate (fructose-1P) to DHAP and glyceraldehyde (GA) or conversion of sedoheptulose 1,7-bisphosphate (sedoheptulose-1,7BP) to DHAP and erythrose 4-phosphate (erythrose-4P), among others. This catalytic versatility of metabolic enzymes could explain why, in the experimentally validated metabolic reconstruction performed in M. pneumoniae (Yus et al., 2009), some of the predicted reactions were not supported by any known enzymatic activity encoded by M. pneumoniae genome.

Here, we addressed whether it is possible to discern active and important metabolic pathways using available omics data, such as proteomics and transposon-determined gene essentiality. The basis for this hypothesis is that, in principle, pathways that produce essential metabolites for the cell must be composed of enzymes that are either essential (e.g., cannot be deleted or disrupted) or necessary for fitness (e.g., disruption triggers a growth impairment). In other words, if the pathway leading to an essential metabolite is unique, all enzymes involved should be essential; in contrast, if there is an alternative pathway with less capacity or whose use could detract from making another important metabolite, the enzymes involved should be for fitness. Enzymes involved in pathways that are not actively used under certain conditions or that generate non-essential metabolites will be non-essential, and their deletion should not compromise bacterial growth. Furthermore, we could imagine that, in general, proteins in a pathway with no branches should exhibit less variation in terms of protein abundance, although proteins upstream or downstream of a branching point will have different concentration than those in the linear pathway and therefore more variability in terms of protein abundance. Depending on the activity of the different branches, protein concentrations will be different for each branch. By combining both concepts, we potentially would be able to predict the activity and importance of metabolic active pathways. This information could be used in metabolic flux analysis or bacterial engineering. In fact, the use of transposon insertional profile analysis has been used in other bacteria for identifying specific metabolic genes in a determined condition (Ochsner et al., 2017) or as a tool to validate existing genomic-based metabolic reconstruction and flux balance analysis (Yang et al., 2014).

To see whether active metabolic pathways could be inferred from proteomics and essentiality data, we selected two bacterial species in the Mycoplasma genus: Mycoplasma pneumoniae and Mycoplasma agalactiae, which comprises species with streamlined genomes and simplified metabolic complexity. For M. pneumoniae, a species that infects the human lung and causes atypical pneumonia (Waites and Talkington, 2004), there is a high-resolution gene essentiality study (Lluch-Senar et al., 2015), metabolic reconstruction (Yus et al., 2009), measurement of metabolites and fluxes (Maier et al., 2013), metabolic modeling, and flux balance analysis (FBA) (Wodke et al., 2013). In the case of M. agalactiae, a metabolic analysis with isotope tracking using different carbon sources is available for the closely related species Mycoplasma bovis (Masukagami et al., 2017). M. bovis and M. agalactiae share 89.6% of their genes (Qi et al., 2012) and have a 99% sequence similarity in their 16S rRNA (Pettersson et al., 1996). Furthermore, for each of the genes involved in carbohydrates, lipids, amino acids, nucleotides, and vitamins metabolism in M. agalactiae, it has been found an orthologous gene in the M. bovis genome evidencing their metabolic analogy (Table S1). For both bacteria, there are high-resolution essentiality studies available (Lluch-Senar et al., 2015, Montero-Blay et al., 2019).

Here, we reconstructed the metabolic pathways using genome and metabolite information available. Then, we experimentally determined carbon sources that allowed robust growth and determined protein relative concentration by mass spectroscopy. Finally, we mapped gene essentiality on the metabolic maps. Comparisons of the metabolic active pathways predicted by our omics analysis with those found in the literature for both bacterial species showed an excellent agreement.

Results

Generation of the Metabolic Maps

We constructed metabolic maps with all possible enzymes involved in carbon metabolism that are capable of producing ATP, as well as with the direct branches coming out of them, into nucleotides, lipids, glycolipids, and glycoproteins for M. pneumoniae and M. agalactiae (Figure 1).

Figure 1.

Figure 1

Genetic Context for Selected Metabolic Genes in M. agalactiae and M. pneumoniae

Panel showing genes involved in glycolipids, glycoproteins, arginine, and sugar metabolism and their link to generate DNA or RNA precursors. Blue circles indicate orthologous genes present in both species, purple circles genes exclusively present in M. pneumoniae, and yellow circles genes present only in M. agalactiae. Pink indicates assigned genes for which the gene assignation is not known. Single asterisks () indicate protein-coding genes participating in multiple reactions in the cell and double asterisks (∗∗) genes whose encoded proteins are described to have multiple functionalities but for which the absence of the antecedent metabolite in one of the species analyzed here suggests that it does not perform that function in that species. Arrows connecting different metabolites indicate directionality of chemical reactions; molecules or cofactors involved in the different reactions are highlighted in squared boxes.

For the generation of the metabolic map, we used genomics data from M. pneumoniae (Himmelreich et al., 1996) and M. agalactiae (Montero-Blay et al., 2019). This information was consistent with KEGG database (Kanehisa and Goto, 2000). Though there are computational methods to fulfil missing reactions or existing metabolic gaps (Karp et al., 2018, Ponce-de-León et al., 2020), the simplicity of Mycoplasmas with around 700 genes allowed us to manually curate the metabolic pathways using the maps for M. pneumoniae of Yus et al. (2009) and Wodke et al. (2013) as references. A table for orthologous genes from M. pneumoniae, M. agalactiae, and M. bovis has been generated in this work (Table S1).

Comparative Genomics Reveals Fundamental Differences in M. agalactiae and M. pneumoniae Carbon Metabolism

At first glance, M. agalactiae and M. pneumoniae appear to share a common core of metabolic reactions (Figure 1, blue circles). However, a more detailed look reveals that M. agalactiae misses some of the pathways involved in carbon metabolism that are present in M. pneumoniae (Figure 1, purple circles). Likewise, there are certain enzymatic activities missing in M. pneumoniae, which are only encoded by M. agalactiae genome (Figure 1, yellow circles).

M. agalactiae lacks genes encoding transporters involved in the metabolism of glucose phosphotransferase system (PTS) (ptsG), fructose and mannose (fruA), mannitol (mtlA), and glycerophosphocholine (glpU). Accordingly with this lack of transporters, all the cytoplasmic processing enzymes whose activity is exclusively involved in the metabolism of these carbon sources are also absent in the genome of M. agalactiae (i.e., fruK for fructose, mtlD for mannitol, and glpQ for glycerophosphocholine). The only exception to this is the maintenance of cytoplasmic enzymes involved in glucose and mannose metabolism that is discussed below.

Regarding carbon metabolism, M. agalactiae has some unique features. Initially, as indicated above, it lacks a PTS-glucose transporter as well as phosphofructokinase (Pfk) and can therefore only enter into glycolysis from the phosphate pentose pathway (PPP) or using glycerol-3P. Second, whereas the genes encoding lactate dehydrogenase, alcohol dehydrogenase, and acetate kinase are present in a single copy in M. pneumoniae genome (i.e., MPN674, MPN564, and MPN533, respectively), these same genes are duplicated in the M. agalactiae genome (MAGA7784_RS00770/MAGA7784_RS02675, MAGA7784_RS02235A/MAGA7784_RS02235B, and MAGA7784_RS00725/MAGA7784_RS02690, respectively). Third, M. agalactiae contains unique genes not present in M. pneumoniae (xfp and gpsA). The enzyme D-xylulose 5-phosphate/D-fructose 6-phosphate phosphoketolase (Xfp) reversibly catalyzes the conversion of D-xylulose to GAP and acetyl-P. This reaction, which is not present in M. pneumoniae, connects the PPP to glycolysis and has been detected in a vast range of organisms, from bacteria to yeast (BRENDA: EC4.1.2.9). The GpsA enzyme converts reversibly glycerol-3P into DHAP, using NADPH as a reducing cofactor. In M. pneumoniae, the reaction connecting glycerol metabolism and glycolysis is irreversible and is catalyzed by GlpD, producing H2O2.

For arginine metabolism, there are genomic but no functional differences between the species: M. agalactiae does not carry any gene involved in arginine metabolism, although M. pneumoniae contains three genes (i.e., arcA, arcB, and arcC) whose protein products could metabolize arginine (to obtain one molecule of ATP). However, whereas this pathway is fully active in other Mycoplasma species (such as Mycoplasma fermentans), M. pneumoniae has lost its ability to metabolize arginine, as indicated by the presence of severe truncations in the genes encoding enzymes of this pathway (Rechnitzer et al., 2013).

For glycolipid metabolism, both species contain a functional pathway to produce uridin diphosphate (UDP)-glucose from glucose-6P. However, the conversion of UDP-glucose to UDP-galactose is only enzymatically supported in M. pneumoniae, but not in M. agalactiae. Both metabolites can be used to generate glycoproteins as well. In line with this, it has been experimentally demonstrated that the levels of UDP-glucose are much higher in the M. agalactiae counterpart, M. bovis, than in the M. pneumoniae–related species M. gallisepticum (Masukagami et al., 2017).

Regarding phospholipid production, both organisms share the same set of genes. However, M. pneumoniae can only import glycerol through a permease (i.e., GlpF), as the predicted ABC transporter for glycerol-3P encoded by its genome has been shown to carry out other functions (Großhennig et al., 2013). In contrast, aside from the GlpF permease, M. agalactiae genome also encodes a dedicated ABC transporter for glycerol-3P that, in contrast with the one predicted for M. pneumoniae, shares a high homology with the validated glycerol-3P uptake system from Escherichia coli.

Filling Gaps in the Metabolic Map

There are genes present in both species (fba and pgi) whose maintenance in M. agalactiae is difficult to explain, given the absence of key enzymes in the import and metabolism of glucose. Fba catalyzes the reversible split of fructose-1,6BP into DHAP and GAP as part of the glycolytic pathway present in M. pneumoniae, and its substrate (i.e., fructose-1,6BP) is produced by Pfk, which is absent in M. agalactiae. However, as mentioned in the introduction, Fba can also reversibly catalyze the synthesis of sedoheptulose-1,7BP from DHAP and erythrose-4P (Vanyushkina et al., 2014) and therefore participate in the PPP. This less-known enzymatic activity of Fba would explain the absence of transaldolase coding gene in both species as well as in other Mycoplasma species (Kamminga et al., 2017, Vanyushkina et al., 2014). Transaldolase is the enzymatic activity that usually connects PPP and glycolysis in most living forms. Of note, the Fba-mediated connection of PPP and glycolysis requires the presence of a sedoheptulose-7P kinase to convert this metabolite into sedoheptulose-1,7BP and/or a phosphatase that performs the opposite reaction (see below). These two metabolites have been identified in M. pneumoniae (sedoheptulose-7P; Maier et al., 2013) and M. bovis (sedoheptulose-7P and sedoheptulose-1,7BP; Masukagami et al., 2017; Table S2). The existence of both metabolites supports the presence of these two activities.

The reversible enzyme Pgi converts glucose-6P into fructose-6P. This step is isolated from the rest of glycolysis in M. agalactiae, as it does not have the Pfk or Pts proteins (Figure 1). On the other hand, there is experimental evidence in M. bovis that 13C-glycerol can be converted into fructose-6P (Masukagami et al., 2017). This suggests the existence of a phosphatase that converts fructose-1,6BP into fructose-6P. The metabolic product of this phosphatase activity would then be converted into glucose-6P, which enters into the glycolipids and glycoproteins pathway that leads to essential cell metabolites. In E. coli, different phosphatases (i.e., YieH, YbiV, YidA, and YaeD) could dephosphorylate fructose-1,6BP into fructose-6P. Of these, YidA is the enzyme with lowest Km (Kuznetsova et al., 2006). M. agalactiae has different sugar phosphatases (e.g., MAGA7784_RS01220, MAGA7784_RS00145, and MAGA7784_RS03930), and one of these is related to YidA in E. coli (MAGA7784_RS03930; Figure S1). Thus, we propose that MAGA7784_RS03930 could catalyze the conversion of fructose-1,6BP into fructose-6P.

Experimental Validation of Carbon Sources Capable of Supporting Growth in M. agalactiae

For M. pneumoniae, the carbon sources capable of promoting growth have been previously analyzed (Yus et al., 2009). This bacterium grows best when using glucose as carbon source but is also able to grow with mannose, fructose, ribose, glycerol, ascorbate (Yus et al., 2009), and phosphoglycerol choline (Großhennig et al., 2013), although to a much lesser extent. However, it cannot use pyruvate, lactate, mannitol, or arginine.

One initial obstacle for determining the carbon sources required for M. agalactiae was our lack of a chemically defined medium in which the compounds present could be controlled. Notably, Mycoplasmas are characterized by their reduced metabolic and biosynthetic capacities. For this reason, the broth used for their growth, termed Hayflick medium, contains animal-derived serum with unspecified composition, complemented by the addition of the preferred carbon source for each Mycoplasma species. The presence of serum in the broth likely explains the modest growth observed for M. agalactiae in plain Hayflick medium without any added carbon source (Table S3). This limited growth could mask the effect of exogenous added carbon sources. To prevent this, we generated a “depleted” version of the rich medium in which all carbohydrate likely provided by the serum have been exhausted (see STAR Methods section; Table S3). We then supplemented this depleted medium with 11 different carbon sources, including phosphatidylcholine, L-arginine, L-lactate, pyruvate, glycerol, fructose, glucose, mannose, mannitol, ribose, and ascorbic acid, and then assessed the growth of M. agalactiae.

No significant growth of M. agalactiae was observed in the depleted medium (Figure 2A). As expected based on the metabolic map (Figure 1), we observed significant growth when the depleted medium was supplemented with ascorbic acid or glycerol (Figure 2A). Supplementing with those sugars requiring metabolic enzymes or transporters absent from the M. agalactiae genome, such as phosphatidylcholine arginine, ribose, glucose, fructose, or mannose, did not lead to significant growth (Figure 2A). We found that lactate and especially pyruvate supported robust growth of the bacterium (Figure 2A; Table S3). This is surprising because these metabolites do not support growth in M. pneumoniae and suggests the presence of specific transporters for these metabolites in M. agalactiae and the existence of a reverse gluconeogenic flow. Only a gluconeogenic flow starting from pyruvate could provide the required precursors for phospholipids and nucleotide metabolism in a depleted medium supplemented with pyruvate.

Figure 2.

Figure 2

Growth Measurement of M. agalactiae under Different Culture Conditions and Secondary Metabolites Measurement for M. agalactiae and M. pneumoniae

(A) Measurement of protein content after 48 h of growth for M. agalactiae cultures, under various culture conditions using different carbon sources in depleted medium.

(B–E) Measurement of glucose consumption or lactate, acetate, or ethanol production in M. pneumoniae (left) or M. agalactiae (right).

(F) Reconstruction of the glycolysis pathway and pyruvate metabolism for M. agalactiae is indicated by black letters. Genes introduced via transposon from M. pneumoniae, to restore complete glycolytic functionality in M. agalactiae, are indicated by pink letters.

(G) Measurement of protein content after 48 h of growth for the synthetic strain of M. agalactiae that has restored glycolysis when using pyruvate or glucose as a carbon source. The number of replicates for the measurements represented in this figure is two. Error bars are representing the range of the distribution.

In agreement with the metabolic maps, glucose is consumed by M. pneumoniae, but not by M. agalactiae (Figure 2B). This is in line with the observation that M. bovis, a species closely related to M. agalactiae, cannot metabolize glucose (Masukagami et al., 2017). M. pneumoniae produces lactate as sub-product of its metabolism (Yus et al., 2009), although M. agalactiae grown in medium with pyruvate seems to consume the traces of lactate present in the non-depleted version of the medium (Figure 2C). Notably, although both species produced acetate, the amount of acetate produced by M. agalactiae was four times that of the concentration measured for M. pneumoniae (3.2 nmol/μL for M. agalactiae versus 0.8 nmol/μL for M. pneumoniae; Figure 2D). Finally, it seems that some ethanol could be produced in M. pneumoniae (Figure 2E).

Overall, when metabolizing glucose, M. pneumoniae generated the metabolic sub-products of lactate, acetate, and, possibly, some ethanol (Table S4). In contrast, M. agalactiae grown in presence of pyruvate mainly generated acetate as sub-product, and lactate was consumed from the medium. These results indicated that, although M. pneumoniae used glycolysis for ATP production (2 ATP per molecule or 4 ATP per molecule of glucose, depending of type of sub-product; lactate or acetate, respectively), M. agalactiae converted lactate, pyruvate, and/or glycerol into acetate to generate only one ATP per molecule. It would also produce two ATPs per molecule when using ascorbate to produce acetate.

Generation of a Synthetic M. agalactiae Strain Capable of Metabolizing Glucose

Glycolysis is an energy conversion pathway used for many organisms to convert glucose to pyruvate. Glucose is the main carbon source used for Mycoplasmas, but the M. agalactiae and M. bovis species are unable to use glucose for ATP production. Strikingly, despite being unable to metabolize glucose, M. agalactiae and M. bovis still conserve eight out of the ten genes involved in the glycolytic pathway. We wondered whether these remaining genes were still functional in glycolysis or could be involved in other functionalities. To address this point, we decided to complement the M. agalactiae genome with the two genes involved in the glycolytic pathway missing in these species (coding for PTS-glucose transporter and Pfk protein). These two proteins are encoded by the genes MPN207 and MPN302, respectively, in M. pneumoniae (Figure 2F). We cloned the genes either together or individually in a transposon under the control of a strong native regulatory region of M. agalactiae (see construct information in Table S5) and transformed these constructs into M. agalactiae. The expression of both heterologous proteins was verified by mass spectrometry (Table S6).

We assessed the ability of the engineered M. agalactiae strains to grow in depleted medium supplemented with glucose as the carbon source. Whereas the single mutants were unable to grow, as inferred from their inability to increase the culture biomass (Table S3), the synthetic strain carrying copies of both MPN207 and MPN302 grew even better than in depleted medium supplemented with pyruvate (Figure 2G). Moreover, this synthetic strain consumed glucose and produced acetate/lactate (Table S4; glucose consumption). Altogether, these results demonstrated that the glycolytic enzymes present in M. agalactiae have retained their functionality and could work in both glycolysis and gluconeogenesis senses.

Proteomics Abundance Quantification Is Associated with Metabolic Pathway Activity

As stated in the introduction, we wanted to find out whether integration of protein copy numbers into a metabolic map could give a clue about the magnitude of metabolic fluxes. To this end, we performed free-label mass spectrometry analyses of M. agalactiae and M. pneumoniae to obtain a quantitative proteome overview of both species (Tables S1 and S7). For visualization, we show the relative protein abundance following a color code based on the log2 normalized average area of the three top peptides of each metabolic enzyme for both species (see STAR Methods section, Figure 3, and Table S1 for orthologous gene protein comparison).

Figure 3.

Figure 3

Proteomics Abundance for Selected Metabolic Pathways in M. agalactiae and M. pneumoniae

Genes whose encoded protein abundance is represented for M. agalactiae growing in pyruvate (A) or M. pneumoniae growing in glucose (B) in urea samples. The color scale represents a gradient according to protein abundance in the set of metabolic enzymes selected, showing a range of minimum (yellow) to maximum (magenta). Proteins with expression levels lower than 27 log2 are shown as min and represented in green. Double asterisks (∗∗) indicates duplicated genes in M. agalactiae. White circles indicate protein-coding genes for proteins with unassigned genes and gray circles undetected proteins by mass spectrometry. A single asterisk () indicates proteins not detected in proteomics samples using urea as lysis buffer but rescued from SDS samples.

Alcohol dehydrogenase (Adh) and lactate dehydrogenase (Ldh) were among the proteins that exhibit larger differences in protein abundance between M. agalactiae and M. pneumoniae. M. agalactiae carries a gene duplication for Adh, and one of the isoforms is more highly expressed in this bacterium than in M. pneumoniae (i.e., 29.0 log2 versus 22.3 log2, respectively). Ldh also has two gene copies in M. agalactiae coding for two different isoforms, named Ldh and LdhA. LdhA showed a moderate expression level (i.e., 28.8 log2) and has limited amino acid identity with Ldh from M. pneumoniae. The Ldh proteins from both species share a high amino acid identity and therefore are likely performing the same role, but their expression levels are quite different (i.e., hereinafter referred to as those protein levels whose difference is >1 log2) in the two species (i.e., 32.6 log2 for M. agalactiae versus 28.7 log2 for M. pneumoniae; 3.89 log2 fold change with p = 0.01).

In addition, there are certain proteins whose relative expression levels are higher in M. pneumoniae than in M. agalactiae. For instance (and as expected), proteins involved in the glycolytic pathway present in both species (i.e., Pgi, Fba, Tim, Gap, Pgk, Gpm, Eno, and Pyk) are predominantly expressed at higher levels in M. pneumoniae than in M. agalactiae. This is especially evident for those enzymes placed in the upper part of the glycolytic pathway (i.e., Pgi, Fba, Tim, and Gap), in which the differences in their relative abundances between the two species are remarkable (i.e., 3.2 log2 fold change p = 0.04, 3.7 log2 fold change p = 0.005, 1.9 log2 fold change p = 0.1, and 2.1 log2 fold change p = 0.6, respectively). This indicates that, for M. pneumoniae, there is a continuous flow from glucose to pyruvate but that, for M. agalactiae, there is a break at the level of Tim, in agreement with its incapability to use glucose (see Discussion).

There are two other proteins related with glycolysis whose relative expression levels are higher in M. pneumoniae than in M. agalactiae: PtsI and Hpr. These proteins are involved in the internalization and subsequent phosphorylation of different carbon sources, such as ascorbate, glucose, mannose, and fructose. Whereas both Hpr and PtsI were highly expressed in M. pneumoniae (29.7 log2 and 28.2 log2, respectively), they were expressed at lower levels in M. agalactiae (27.7 log2 and 24.1 log2, respectively, and 2.0 log2 fold change p = 0.001; 4.1 log2 fold change p = 0.09 for Hpr and PtsI). This observation can be explained by the fact that M. pneumoniae has more carbon-source transporters that require the use of Hpr and PtsI than M. agalactiae. For the PPP, the expression of the transketolase (Tkt) enzyme was also higher in M. pneumoniae than in M. agalactiae (28.2 log2 versus 24.8 log2, respectively). This enzyme not only catalyzes an intermediate reaction in the PPP but is also the unique entry point to the PPP from glycolysis in M. pneumoniae; in contrast, M. agalactiae can also connect to the PPP through the more abundant Xfp enzyme. For ascorbate, both species showed lower but close to similar (hereinafter referred to as those differences ≤1 log2) abundances (27.8 log2 for M. pneumoniae and 26.7 log2 for M. agalactiae), suggesting that this metabolite has a subsidiary role as a carbon source.

Finally, for the metabolism of glycerol/phospholipids as well as glycolipids/glycoproteins, we see similar low levels (e.g., for GlpK enzyme 27.3 log2 and 26.5 log2 for M. pneumoniae or M. agalactiae, respectively) for the enzymes involved in both species. In summary, for M. agalactiae, higher expression levels are found in those enzymes involved in pyruvate and lactate metabolism, although for M. pneumoniae, higher expression levels are found in general for all glycolytic enzymes and proteins involved in carbohydrate import.

As a general observation derived from the proteomics analysis, proteins belonging to a section of metabolic pathways without bifurcation points (hereinafter referred to as sub-pathways) tend to have similar expression levels. To further demonstrate this, we defined a set of linear sub-pathways for both M. pneumoniae and M. agalactiae (see STAR Methods). Subsequently, the coefficients of variation (CV) for protein abundance were calculated for each individual sub-pathway (observed) as well as for artificial sub-pathways whose members were randomly sampled from the set of metabolic genes of each strain (expected; Table S8; Figure S2). In general, most of the observed sub-pathways showed less CV than expected. However, some exceptions to this trend are observed. For instance, sub-pathway two in M. pneumoniae showed a CV similar to the expected if genes were randomly sampled. This might be related with the fact that genes belonging to this sub-pathway are expressed at low levels (i.e., close to the detection limit), which could impair accurate protein abundance determination. Of note, despite these exceptions, when the CV of all the sub-pathways analyzed for M. pneumoniae were pooled together, the mean of them was significantly lower than the one observed for artificial sub-pathways for natural quantification or log2 transformed values, respectively (Figures 4A and 4B). Moreover, a similar result was obtained in the M. agalactiae analysis (Figures 4C and 4D). These results support the idea that linear sub-pathways have less variation in protein abundance than expected by chance. Furthermore, this correlation in protein abundance cannot be explained by operon composition, as numerous members of the analyzed sub-pathways belong to different transcriptional units (Table S9). Therefore, similar protein expression levels in consecutive proteins might be taken as an indication of a functional pathway lacking bifurcation points. Strikingly, this correlation in protein abundance for enzymes belonging to the same sub-pathway seems to be a dynamic phenomenon. In fact, M. pneumoniae naturally expresses low levels of enzymes related with fructose metabolism and consequently grows poorly when this sugar is added as major carbon source. However, adaptation to this sugar (i.e., several passages with fructose as main carbon source present in the medium) results in a significant increase of the expression levels of those genes involved in fructose metabolism (Yus et al., 2009; Figure S3).

Figure 4.

Figure 4

Study of the Protein Variability in Linear Pathways

For each of the strains, the coefficient of variation (CV) (standard deviation corrected by the mean) for linear sub-pathways was calculated and pooled together. In box plot (A and B) for M. pneumoniae and (C and D) for M. agalactiae using raw quantification values and a log2 transformation, respectively, is shown. In purple is represented the pooled CV from the set of sub-pathways and in green the pooled expected CV calculated based on artificial sub-pathways whose members were randomly sampled from the set of metabolic genes of each strain. The p-values obtained for M. pneumoniae are p = 0.005 and p = 0.012 for raw and log2 values, respectively. For M. agalactiae, the p-values obtained are for raw and log2 values, respectively, p = 0.045 and p = 0.008.

High-Resolution Transposon Density and Its Application for Flux Metabolic Directionality Ascertainment

We propose that gene essentiality could provide insights about the activity of different metabolic pathways of a cell, which together with information about protein abundance would complement the information provided by metabolomics studies. The assumption behind this is that the level of essentiality of a gene will be related to the importance of the pathway and the flux that goes through it. However, this exclusively applies for essential and fitness genes, although for non-essential genes, the flux going through it does not necessarily have to be zero.

To address this, we plotted the metabolic maps of M. agalactiae and M. pneumoniae together with a color-coded scale of transposon insertion density (see STAR Methods, Figures 5A and 5B, and Table S10). Insertion density is related to the impact that disruption of the gene has on the fitness of the bacterium (Lluch-Senar et al., 2015, Montero-Blay et al., 2019).

Figure 5.

Figure 5

Insertional Transposon Density Landscape for M. agalactiae and M. pneumoniae for Selected Metabolic Enzymes

Sets of metabolic genes in M. agalactiae in presence of pyruvate (A) or in M. pneumoniae in presence of glucose (B) are represented in a color gradient, with gene-insertional transposon density adjusted to the specific coverage obtained for each of the strains. Minimal transposition density is indicated by magenta (showing a more essential profile), and maximum transposon density is represented in white (showing a non-essential profile). Blue circles indicate predicted genes but still unassigned. Duplicated genes for M. agalactiae are displayed with an asterisk ().

Our essentiality/metabolic map in M. agalactiae reflected an essential footprint along all the genes involved in converting pyruvate into acetate (i.e., the four subunits of the pyruvate dehydrogenase complex, NADH oxidase, phosphate acetyltransferase, and acetate kinase). Out of the two copies, the more abundantly expressed ack gene showed an essential profile (shown in magenta), whereas the other less-abundant isoform was clearly non-essential (shown in white). This divergence in the essentiality profile suggests that these two isoforms have different functionalities, as if they were performing the same role it would impossible to find an essential character for any of the isoforms. Conversely, the lactate-related genes ldh and ldhA were found as fitness under these conditions. This falls in line with the fact that M. agalactiae, in order to generate ATP, produces acetate rather than lactate as main sub-product of pyruvate metabolism. Unfortunately, the dispensability of the lactate pathway in M. agalactiae prevents to ascertain whether the two isoforms Ldh and LdhA have the same function. In contrast, in M. pneumoniae, the entire pathway from pyruvate to acetate showed a fitness footprint, as did the Ldh enzyme. This is expected, as M. pneumoniae glycolysis produces two ATPs before bifurcation into lactate or acetate and therefore does not need the ATP produced when going from pyruvate to acetate.

Even though M. agalactiae is unable to use glucose as a carbon source, the genes pyk, eno, gpm, pgk, and gap involved in the lower part of the glycolytic pathway showed an essential profile. This was not the case for the Fba and Pgi enzymes (discussed above). As the essentiality map was performed with pyruvate as the main carbon source, this suggests the existence of a gluconeogenic flux (i.e., reverse glycolysis) from pyruvate to GAP in this bacterium. The essential footprint extended across most of the genes (i.e., xfp, rpi, rpe, deoB, and prps) involved in the conversion of GAP to 5-phospho-D-ribosyl α-1-pyrophosphate (PRPP), ribose-5P, and ribose-1P, all of which are critical precursors for DNA and RNA metabolism. The xfp gene shows a fitness profile that can be explained, as the role of Xfp converting GAP into xylulose-5P can also be mediated by Tkt, and further agrees with the fact that we did not observe growth of M. agalactiae with ribose. In M. pneumoniae, the entry into ribose-5P and ribose-1P could be direct, as it can grow on ribose (as shown its presence in human serum in a range of 7–100 μM; see Table S11) and as indicated by the non-essential character of the rpe and rpi genes and the very low fitness for Tkl.

The whole metabolic pathway of ascorbic acid is clearly non-essential in both species. This pathway would represent a route for generation of nucleotide precursors that would not require a connection of GAP to the PPP. This suggests that the amount of ascorbic acid present in the medium in which both species are grown is rather low (see Table S11) and, consequently, that the generation of DNA and RNA precursors is performed mainly through the link of glycolysis/gluconeogenesis to the PPP in M. agalactiae and/or by importing ribose in M. pneumoniae.

Lastly, looking into the glycerol pathway, we found that the glycerol permease (GlpF) is fitness in both M. agalactiae and M. pneumoniae. We also saw that GlpD, which links glycerol to glycolysis in M. pneumoniae, was not essential. GpsA, which does the same in a reversible manner, is fitness in M. agalactiae. In M. pneumoniae, we found that glucose is not converted to glycerol-3P (Maier et al., 2013). Glycerol-3P is essential for generating phospholipids and therefore it should be provided by transport and phosphorylation of glycerol and/or by hydrolysis of phosphatidylcholine present in the serum that complements the medium. These two possible ways of obtaining glycerol-3P explain the fitness character of both pathways observed in M. pneumoniae. In contrast, M. agalactiae does not have the enzymes required for production of glycerol-3P from phosphatidylcholine, and it therefore needs to import glycerol by (1) the GlpF permease, (2) glycerol-3P through the glycerol ABC transporter, or (3) obtain it from DHAP via GpsA. Again, this redundancy of pathways to obtain glycerol-3P in M. agalactiae explains the fitness character of the genes involved in all these pathways. In this respect, it is worth noting that a small amount of glycerol is required for growth in M. pneumoniae, suggesting it could have another role aside from generating glycerol-3P (Yus et al., 2009).

In summary, our essentiality maps agree with our metabolic maps and experimental analyses of carbon sources. We observed that M. agalactiae could be performing a reverse glycolysis to enter into the PPP to generate nucleotide precursors. M. pneumoniae uses glucose to produce ATP through the glycolytic pathway but also links this pathway to the PPP to generate nucleotide precursors.

Discussion

The ascertainment of essential and active or non-active metabolic pathways is the starting point for performing metabolic engineering for different purposes, such as the development of vaccination strains, deletion of virulence factors, or the enhancement of biosynthetic capacities. However, even for Mycoplasmas, which are bacterial cells characterized by their limited biosynthetic pathways, metabolism constitutes an intricate and interconnected network of reactions.

In this work, we integrated genomics, proteomics, and gene essentiality data at high resolution for M. agalactiae and M. pneumoniae as an example of how to elucidate metabolic active pathways without experimental metabolomics determination. These predictions are validated by FBA analysis in M. pneumoniae and experimental information collected previously for M. pneumoniae (and its closely related species, M. gallisepticum, and in the case of M. agalactiae, for the closely related species M. bovis; Masukagami et al., 2017). These two species share 100% of all enzymes involved in metabolic pathways linked to the use of carbon sources (Table S1).

First, we manually reconstituted the metabolic map regarding the use of carbon sources to produce energy and its connections to nucleotides, lipids, glycolipids, and glycoproteins. Besides postulating the existence of additional players to fulfil the logics of the pathway architecture, we also propose alternative functionalities for proteins. The proposal of specific glycolytic enzymes with multiple functionalities has been contemplated previously for Mycoplasmas (Pollack et al., 2002). In M. pneumoniae, the pyruvate kinase produces nucleosides triphosphate (NTP), thereby replacing a nucleotide diphosphate kinase. This cannot happen in M. agalactiae when using pyruvate as carbon source, which gives gluconeogenesis, but not glycolysis. Thus, we propose that acetate kinase genes could be involved in the generation of NTPs. It has been described that this enzyme can also use cytidine diphosphate (CDP), guanosine diphosphate (GDP), inosine diphosphate (IDP), thymidine diphosphate (TDP), or UDP (BRENDA:EC2.7.2.1). We then combined all experimental evidence for active metabolic fluxes in M. agalactiae (mainly coming from M. bovis; Masukagami et al., 2017) and in M. pneumoniae (Yus et al., 2009, Maier et al., 2013, Wodke et al., 2013; Figures 6A and 6B, respectively). In both cases, we have experimental data regarding (1) carbon sources that allow growth, (2) metabolites identified, and (3) 13C-glucose and/or 13C-glycerol fluxes. For M. pneumoniae, the majority of the metabolites shown in Figure 6 were detected, indicating that the different pathways shown are active (to various extents). We have experimental evidence showing a limited flux of glucose going into the PPP or the phospholipid pathway (Maier et al., 2013) and a major flux going to acetate and lactate production. However, both pathways can be used, as M. pneumoniae can grow not only on ribose and ascorbate but also on glycerol or phosphatidylcholine. For M. agalactiae, experiments with 13C-glucose and 13C-glycerol (from M. bovis; Masukagami et al., 2017) demonstrate that there is no flux from glucose to glycolysis and that glycerol is used not only for making phospholipids but also to enter into gluconeogenesis, thereby linking glucose-6P to the generation of glycolipids and glycoproteins. Furthermore, the growth of this bacterium with glycerol or ascorbate shows that, in the absence of pyruvate and lactate, it can carry out at least a set of the reactions involved in the canonical glycolysis. This is further supported by our finding that the introduction of the missing Pfk and PTS-glucose transporter enzymes enables M. agalactiae growth using glucose as carbon source. Thus, this bacterium could perform glycolysis or gluconeogenesis, depending on the availability of carbon sources.

Figure 6.

Figure 6

Integration of Metabolic Information Collected for M. agalactiae and M. pneumoniae to Date with the Metabolic Information Observed in This Work

(A) For M. agalactiae, pink indicated integration of metabolic active pathways predicted in this work for nucleotide precursors, blue metabolic pathways for obtaining energy, green metabolic pathways for generating glycolipids or glycoproteins, and yellow metabolic pathways linked to phospholipids metabolism. Red letters indicate metabolites detected for M. bovis, and blue letters indicate possible metabolites identified in the same work (Masukagami et al., 2017). Orange arrows indicate active metabolic fluxes inferred from metabolomics studies for M. bovis (Masukagami et al., 2017).

(B) Integration of metabolic information inferred from this work for M. pneumoniae with experimental information collected in previous works. Metabolic active pathways proposed here for nucleotide metabolism are highlighted in pink, those involved in pathways for energy generation in blue, metabolic pathways for glycolipids and glycoproteins production in green, and phospholipids metabolism in yellow. Red letters indicate metabolites identified previously for M. pneumoniae (Maier et al., 2013) and blue letters metabolites whose masses make it difficult for precise ascertainment. Green arrows indicate metabolic pathways described for M. pneumoniae in Großhennig et al. (2013), pink arrows metabolic pathways predicted in Maier et al. (2013), orange arrows metabolic fluxes predicted for M. gallisepticum in Masukagami et al. (2017), and blue arrows active metabolic pathways ascertained from experimental validation for M. pneumoniae in Yus et al. (2009).

We have also integrated the experimental data analyzed in this manuscript from genomics, gene transposon density, and proteomics data for M. pneumoniae and M. agalactiae to postulate active metabolic pathways for their metabolism of carbohydrates, nucleotide precursors, glycolipids, and phospholipids when grown with glucose or pyruvate, respectively, and compared that to the ones determined experimentally (Figures 6A and 6B for M. agalactiae and M. pneumoniae, respectively).

In M. agalactiae, when grown on medium with pyruvate, ATP production is mediated by the conversion of pyruvate to acetate, as indicated by the essential footprint and high abundance of all enzymes involved in this metabolic conversion. The enzyme catalyzing the conversion of lactate to pyruvate (i.e., Ldh) is not essential. However, the high expression levels of Ldh in M. agalactiae suggest that the production of ATP from lactate might be a common phenomenon for this species. We showed that M. agalactiae can grow using either ascorbate or glycerol as a carbon source. However, the enzymes involved in glycerol import and its phosphorylation or in ascorbate metabolism have a fitness profile or are non-essential, respectively. This is logical, as pyruvate was the main carbon source in our essentiality study. Glycerol, although essential for phospholipids, can be obtained by two different transport systems as well as from gluconeogenesis.

The generation of nucleotide precursors using pyruvate as carbon source in M. agalactiae follows a strategy based on a gluconeogenic flux (i.e., reverse glycolysis) from pyruvate to GAP. This hypothesis is supported by the essentiality footprint found for all the genes involved this metabolite conversion, despite the fact that the glycolytic pathway is truncated in this bacterium. To finally enter into the PPP and produce in this way nucleotide precursors, GAP has to be converted to xylulose-5P as a first step. In M. agalactiae, this conversion of GAP to xylulose-5P can be mediated by either Tkt or Xfp. Tkt needs fructose-6P and GAP to do this. However, we observed that, although this metabolite (fructose-6P) can be produced by phosphatase hydrolysis of fructose-1,6BP, the abundance of Fba was significantly lower than that of the downstream glycolytic enzymes (Figure 3A). This, together with the low essentiality profile of Fba and the quasi-essential character of the xfp gene for M. agalactiae, seems to indicate that this conversion is mainly performed by Xfp. Indeed, this assumption is further supported by the expression levels of these enzymes in M. agalactiae, as that for Xfp (i.e., 29.3 log2) is much higher than that for Tkt (i.e., 24.8 log2). Thus, in M. agalactiae, there is a flux starting at pyruvate and ending in ribose-5P that enables the synthesis of nucleotide precursors, such as PRPP.

We postulate that synthesis of glycolipids and glycoproteins might be mediated by two different fluxes in M. agalactiae. We propose that, in M. agalactiae, glucose-6P, the major building block for glycolipids synthesis, can be generated thanks to the existence of a complete gluconeogenic flux from pyruvate to glucose-6P. In this way, the consecutive activity of the glycolytic enzymes Pyk, Eno, Gpm, Pgk, Gap, and Fba, as well as a putative phosphatase, most likely the YidA-related phosphatase encoded by MAGA7784_RS03930 (Figure 6) would enable this conversion. All the genes coding for these enzymes show an essential profile (e.g., pyk, eno, gpm, pgk, and gap) or a quasi-essential profile (e.g., pgi and fba). Alternatively, the generation of glucose-6P could be mediated by a partial gluconeogenic flux starting at glycerol. However, as discussed in the previous section, M. agalactiae can only produce glycerol-3P from DHAP or import glycerol or glycerol-3P, but it cannot produce it from phosphatidylcholine. The fitness profile of the respective enzymes suggests that these pathways are all active. Finally, we observed that all the enzymes going from glycerol-3P to phospholipids have an essential profile in both M. agalactiae and M. pneumoniae. This indicates the importance of generating glycerol-3P.

Whereas most of our predictions are based on the essentiality study done for M. agalactiae, the proteomics data strongly appear to corroborate our hypothesis. In fact, it is curious to observe that expression levels of all the enzymes involved in the lower part of the glycolytic pathway (i.e., Gap, Pgk, Gpm, Eno, and Pyk) are higher than the ones observed for the enzymes found in the upper part (i.e., Fba and Pgi). This observation falls in line with the fact that the lower part of the glycolytic pathway feeds both nucleotide metabolism and glycolipids metabolism, whereas the enzymes in the upper part are intended to exclusively feed glycolipid metabolism. In contrast, M. pneumoniae shows a different metabolic strategy. In this species, ATP generation is mediated through glycolysis, as indicated by the protein abundance and having an essential footprint present of all the enzymes in the whole pathway from glucose to pyruvate. Through this set of reactions, two molecules of ATP are obtained, which can be increased to four if pyruvate is further metabolized to acetate rather than to lactate. Alternatively, under glucose depletion conditions, M. pneumoniae can also use alternative carbon sources, such as fructose or mannose, which enter glycolysis at different point-load levels.

Regarding the PPP, M. agalactiae can link glycolysis and the PPP using the activity of either Tkt or Xfp, but the genome of M. pneumoniae only encodes for Tkt. Intriguingly, however, the tkt gene shows a low fitness character in both species, which makes sense for M. agalactiae, given the alternative route based on Xfp, but not for M. pneumoniae, which lacks the xfp gene. The reason could be that M. pneumoniae can use ribose as carbon source as well as import nucleosides (Yus et al., 2009), although M. agalactiae does not grow with ribose. Finally, the link to glycolipids metabolism is quite obvious in M. pneumoniae, given its ability to directly import and phosphorylate glucose into glucose-6P, which can be later employed for glycolipids synthesis. Regarding phospholipids in M. pneumoniae, the enzymes downstream of glycerol-3P are essential and have as M. agalactiae similar expression levels, although those involved in glycerol-3P generation have a fitness profile, as the bacterium has three possible routes: from fructose-1P; from phosphatidylcholine; and by importing it directly. Essentiality analysis suggests that the fructose flux must be very low. In this case, glycolysis cannot produce glycerol-3P, as the GlpD enzyme produces DHAP from glycerol-3P in an irreversible manner.

The study of bacterial metabolism may give a hint about their lifestyle within a host. In the case of M. pneumoniae, a lung-colonizing bacterium, the essentiality profile for its active metabolic pathways might be different in in vivo conditions, where phosphatidylcholine and phosphatidylglycerol are the main carbon sources present in the lung alveolar surfactant. The fact that M. agalactiae or M. bovis have the ability to metabolize acetate or pyruvate, products of glycolysis, could suggest that they could internalize into the cytoplasm of eukaryotic cells (Bürki et al., 2015) and use pyruvate as substrate.

Summing up, integration of the metabolic pathway genomics, the experimental analysis on carbon sources supporting growth, the quantitative proteome, and the essentiality analyses allows us to predict the metabolic pathways active under the conditions studied. Notably, our predictions agree not only with the metabolic studies done in M. pneumoniae and M. bovis but also with the experimental validation of carbon sources capable to promote bacterial growth done in this study. Also, in a metabolic reconstruction performed in minimal cell JCVI-syn3A, the usefulness of gene essentiality and proteomics to help reconstructing the metabolic activity of the bacterium was also shown (Breuer et al., 2019). Thus, protein quantification together with gene essentiality under different experimental conditions could be a way to complement metabolic flux analyses that use 13C-tagged compounds or metabolic modeling. To conclude, it should be noted that, although in some aspects the information provided by proteomics and gene essentiality might seem redundant, both approaches support each other and offer complementary information. Gene essentiality shows essential pathways and, when more than one pathway is connected to an essential metabolite, indicates whether they can replace each other. Protein abundance in pathways connected to a metabolite gives an indication of the preferred flow. Combination of both could offer additional insights. In M. pneumoniae, the expression levels of proteins converting pyruvate into lactate and acetate are comparable. Notwithstanding, the essentiality profile of those genes differs, showing ldh a lower density of transposon insertions and therefore pointing to lactate as main metabolism sub-product for M. pneumoniae. On the other hand, there are other situations in which proteomics data could clarify the information provided by gene essentiality. For instance, when there is redundancy in the pathways to produce a given metabolite, such as xylulose-5P in M. agalactiae, the essentiality profile could suggest which pathway is absorbing most of the flux (i.e., xfp is much more essential than the alternative pathway based on fba and tkt encoded activities), but this can be further corroborated with protein abundance (i.e., Xfp is detected at levels almost ten times higher than Tkt).

STAR★Methods

Key Resources Table

REAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Virus Strains

Mycoplasma pneumoniae M129 Colleague Richard Herrmann
Mycoplasma agalactiae 7784 Colleague Christine Citti
Mycoplasma agalactiae MPN302+MPN207 synthetic strain This paper NA
Escherichia coli 5-alpha High Efficiency NEB C2987P

Chemicals, Peptides, and Recombinant Proteins

L-phosphatidylcholine Sigma-Aldrich Cat#61755-25G
Ethanol Merck Millipore Cat#108543
Glycerol Sigma-Aldrich Cat#G5516-1L
D-Fructose Sigma-Aldrich Cat#F0127-10MG
D-Glucose Sigma-Aldrich Cat#D8270-1KG
D-Ribose Sigma-Aldrich Cat#R1757-10G
D-Mannose Sigma-Aldrich Cat#M6020-25G
D-Mannitol Sigma-Aldrich Cat#M4125-100G
Sodium Pyruvate Sigma-Aldrich Cat#P2256-25G
L-Ascorbic Acid Sigma-Aldrich Cat#A0278-25G
L-Lactic Acid Sigma-Aldrich Cat#199257-5G

Critical Commercial Assays

Ethanol Assay Megazyme K-ETOH
Glucose Colorimetric/Fluorometric Assay Kit Biovision Cat#K606
Lactate Colorimetric/Fluorometric Assay Kit Biovision Cat#K607
Acetate Colorimetric/Fluorometric Assay Kit Biovision Cat#K658
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Cat#23225

Deposited Data

Proteomics raw data for M. pneumoniae M129 This paper Pride repository:
PXD015800
Proteomics raw data for M. agalactiae 7784 This paper Pride repository:
PXD015800
Proteomics raw data for synthetic strain M. agalactiae This paper Pride repository:
PXD015800

Recombinant DNA

pMTnGm-SynMyco + EF-tu-MPN207 + EF-tu-MPN302 See Table S5 This work Addgene ID: 145779
pMTnGm-SynMyco + EF-tu-MPN207 See Table S5 This work N/A
pMTnGm-SynMyco + EF-tu-MPN302 See Table S5 This work N/A

Software and Algorithms

Proteome Discoverer Software 2.0 Thermo Fisher Scientific https://www.thermofisher.com/order/catalog/product/OPTON-30795
Mascot Search Engine 2.6 Matrix Science http://www.matrixscience.com/mascot_support_v2_6.html
Microbial Genomes Database Default values MGDB http://mbgd.genome.ad.jp/
BlastP BlastP suite https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome
Python 3.6 Python Software Foundation https://www.python.org
Statsmodel Python 3.6 Seabold and Perktold, 2010 Python package
Matplotlib Python 3.6 Hunter, 2007 Python package
RandomPackage Python 3.6 Lib/random.py Python package
Scipy Python 3.6 Virtanen et al., 2020 Python package
DOOR database Mao et al., 2009 http://161.117.81.224/DOOR2/

Resource Availability

Lead Contact

Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Luis Serrano (luis.serrano@crg.eu).

Materials Availability Statement

Plasmid generated in this work has been deposited in Addgene: ID 145779.

Data and Code Availability Statement

This study generated unique proteomics datasets. The datasets generated have been deposited in Pride Repository ID PXD015800. The code supporting this work is available in the following link https://github.com/CRG-CNAG/MetabolicPathVariationCoeff

Experimental Model and Subject Details

The strain 7784 was used for wild-type M. agalactiae (kindly provided by Dr. Christine Citti), and the strain M129, for wild-type M. pneumoniae (ATTC 29342, subtype 1). Both species were grown at 37°C in standard Hayflick medium (for each adjusted 500 mL of Hayflick medium at pH 7.6 it contains 7.3 g PPLO broth, 10 μg phenol red, 11.9 g HEPES, 100 mL inactivated fetal horse serum, and 500,000 units sterile penicillin G) supplemented with 0.5% sodium pyruvate, pH 7.6 (Sigma-Aldrich) for M. agalactiae or 0.5% glucose, pH 7.6 (Sigma-Aldrich) for M. pneumoniae. When indicated, M. agalactiae was grown in ‘depleted Hayflick medium’ supplemented with the desired carbon source. M. agalactiae was grown in suspension (180 rpm, 37°C), while M. pneumoniae was grown attached to a flask without shaking at 37°C.

Method Details

Experimental metabolic analysis of M. agalactiae

We started all experiments with a protein concentration of 2 μg/ml of M. agalactiae cells in the depleted medium. “Depleted medium” was generated by inoculating 2 L of complete Hayflick medium (lacking pyruvate) with M. agalactiae, growing at 37°C with 180 rpm orbital shaking for 48 h, centrifuging twice at 9408 g for 10 min at 4°C, discarding the pellet, and filtering the medium using Stericup®-GP Filter Units polyethersulfone membrane (0.22 μm pore size) (Millipore Express® PLUS, Z660507-12EA). Depleted medium was stored at 4°C until use, and a single batch was used for all experiments in this work when indicated. Different carbon sources were prepared in concentrated stocks and then diluted to a fixed final concentration. All components analyzed were dissolved in sterile Milli-Q water except L-α-phosphatidylcholine, which was dissolved in ethanol (Merck, 108543). The final concentration used was 0.174% for L-arginine (Sigma-Aldrich, A5006-100), 4x10−3% for L-α-phosphatidylcholine (Sigma-Aldrich, 61755-25G), 0.05% for glycerol (Sigma-Aldrich, G5516-1L), and 0.1% for D-fructose (Sigma-Aldrich, F0127-10MG), D-glucose (Sigma-Aldrich, G8270-1KG), D-ribose (Sigma-Aldrich, R1757-10G-A), D-mannose (Sigma-Aldrich, M6020-25G), D-mannitol (Sigma-Aldrich, M4125-100G), sodium pyruvate (pH adjusted to 7.8; Sigma-Aldrich, P2256-25G), L-ascorbic acid (pH adjusted to 7.8; Sigma-Aldrich, A0278-25G), and L-lactic acid (provided in solution, pH adjusted to 7.3; Sigma-Aldrich, 199257-5G,). For each culture, M. agalactiae stock was inoculated in 50 mL Falcon tubes (Fisher Scientific, 14-432-22) filled with 10 mL depleted medium supplemented with the different carbon sources. After 48 h of growth, cultures were centrifuged twice and washed with one ml PBS before final resuspension in 250 μL of lysis solution (4% SDS, 100 mM HEPES). Growth was measured by protein content using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 23225) following manufacturer’s protocol. For growth curves based on protein content for M. agalactiae WT and growth comparison of M. agalactiae WT in Hayflick medium versus the depleted version see Table S3.

Generation of a M. agalactiae strain able to metabolize glucose

Wild-type M. agalactiae was transformed via transposon with two M. pneumoniae genes using plasmids described in Table S5. The transposon plasmid was generated following the Gibson assembly method (Gibson et al., 2009). DNA was isolated from NEB® 5-alpha High Efficiency (C2987P). Clones were isolated using LB agar plus ampicillin (100 μg/ml) plates and confirmed by sequencing (Eurofins Genomics). Cultures of M. agalactiae (25 ml) were grown 48 h in Hayflick medium. After, medium was removed, and 10 mL fresh Hayflick medium was added. After 3 h, cultures were centrifuged at 9408 g at 4°C, washed three times with chilled electroporation buffer (EB; 272 mM sucrose, 8 mM HEPES, pH 7.4), and resuspended in 300 μl chilled EB. Cells (50 μl) were then mixed with 1.5 μg DNA, incubated 20 min on ice, and electroporated in 0.1-cm electro cuvettes using a BIO-RAD Gene Pulser Xcell apparatus, using the settings of 1250 V / 25 μF / 100 Ω. Immediately after the pulse, 420 μl fresh Hayflick was added, and cells were incubated for 90 min (M. agalactiae) at 37°C before seeding on agar plates. Culture (100 μl) was then inoculated into 10 mL Hayflick medium with 100 μg/ml gentamicin, 0.25% glucose, and 0.25% pyruvate for a progressive metabolic adaptation. After 4 days, cultures were centrifuged at 9408 g, medium was discarded, and the cell pellet was resuspended in 10 mL Hayflick medium with 1% glucose and 100 μg/ml gentamicin and grow further. After 2 days, the culture of M. agalactiae strain was collected in 1 mL of Hayflick medium to generate the primary stock of cells. The expression of both heterologous proteins from M. pneumoniae in M. agalactiae have been detected by mass spectrometry (Table S6). The growth of M. agalactiae synthetic strain double mutant (expressing both heterologous proteins) or single mutants (expressing only single protein; or MPN207 or MPN302) has been assessed by protein content after 24 hours of growth in the depleted version of the medium supplemented with glucose (Table S3).

Secondary metabolite measurement

For each metabolite the concentration was measured at the initial point and then after 48 h of growth. M. agalactiae and M. pneumoniae cultures were grown for 48 h in standard Hayflick medium (supplemented with pyruvate or glucose, respectively). For M. agalactiae, the culture was centrifuged at 4°C for 10 min at 9408 g, and the supernatant was collected and placed on ice. For M. pneumoniae (which grows attached), supernatant was collected directly and placed on ice. Concentrations were measured for ethanol with the enzymatic kit for ethanol assay (Megazyme, K-ETOH), for glucose with the Glucose Colorimetric/Fluorometric Assay Kit (Biovision, #K606), for L-lactate with the Lactate Colorimetric/Fluorometric Assay Kit (Biovision, #K607), and for acetate with the Acetate Colorimetric Assay Kit (Biovision, #K658); all methods followed the manufacturers’ instructions. Analyses of the different metabolites were performed on different days and collected in Table S4.

Preparing samples for mass spectrometry analysis

For M. pneumoniae, 50 μg of cells were inoculated in two T25 flask with 5 mL Hayflick medium supplemented with glucose 0.5% and grown for 48 h. Cells were then washed twice with PBS and scraped for final collection in a 1.5 mL collection tube. For M. agalactiae, 5 mL cultures inoculated in Falcon tubes were grown for 48 h in standard Hayflick medium supplemented with sodium pyruvate 0.5%. Cultures were then centrifuged and washed twice in PBS. For both species, pelleted cells were then resuspended ten times with a 25-gauge needle to separate individual cells and resuspended in 150 μL of urea lysis buffer (6 M urea, 0.2 M NH4CO3) or SDS lysis buffer (4% SDS, 100 mM HEPES). For samples resuspended in urea buffer, two biological replicates were performed for each species. The protein concentration of each lysate was measured using the Pierce BCA Protein kit following manufacturer’s protocol. For urea samples, 10 μg of lysate samples were reduced with 30 nmol dithiothreitol (37°C, 60 min) and alkylated in the dark with 60 nmol iodoacetamide (25°C, 30 min). The resulting protein extract was first diluted to 2 M urea with 200 mM ammonium bicarbonate for digestion with endoproteinase LysC (1:10 LysC weight: Cell lysate weight, overnight at 37°C; Wako, cat # 129-02541) and then diluted 2-fold with 200 mM ammonium bicarbonate for trypsin digestion (1:10 w:w, 8 h at 37°C; Promega, cat # V5113). Samples with SDS lysis buffer were reduced with 90 nmol dithiothreitol (30 min at 56°C) and alkylated in the dark with 180 nmol iodoacetamide (30 min at 25°C). Following the filter-aided sample preparation (FASP) method described in Wiśniewski, 2016, samples were then digested with 3 μg LysC (Wako, cat # 129-02541) overnight at 37°C, and then with 3 μg of trypsin (Promega, cat # V5113) for eight hours at 37°C. After digestion, peptide mixes were acidified with formic acid and desalted with a MicroSpin C18 column (The Nest Group, Inc) prior to LC-MS/MS analysis.

Chromatographic and mass spectrometric analyses

Samples were analyzed using a LTQ-Orbitrap Velos Pro-mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) coupled to an EASY-nLC 1000 (Thermo Fisher Scientific (Proxeon), Odense, Denmark). Peptides were loaded onto a 2-cm Nano Trap column with an inner diameter of 100 μm packed with 18C particles of 5 μm particle size (Thermo Fisher Scientific) and separated by reversed-phase chromatography using a 25-cm column with an inner diameter of 75 μm, packed with 1.9 μm 18C particles (Nikkyo Technos Co., Ltd. Japan). Chromatographic gradients started at 93% buffer A, 7% buffer B with a flow rate of 250 nl/min for 5 min, and gradually increased to 65% buffer A, 35% buffer B over 120 min. After each analysis, the column was washed for 15 min with 10% buffer A, 90% buffer B. Buffer A was 0.1% formic acid in water, and buffer B, 0.1% formic acid in acetonitrile. The mass spectrometer was operated in positive ionization mode with nano spray voltage set at 2.1 kV and source temperature at 300°C. Ultramark 1621 was used for external calibration of the FT mass analyzer prior to analyses, and an internal calibration was performed using the background polysiloxane ion signal at m/z 445.1200. Acquisition was performed in data-dependent acquisition (DDA) mode, and full MS scans with 1-micro scans at a 60,000 resolution were used over a mass range of m/z 350–2000 with detection in the Orbitrap. Auto gain control (AGC) was set to 1 ⋅ 106, dynamic exclusion (60 s) and charge state filtering disqualifying singly charged peptides was activated. In each cycle of DDA analysis, following each survey scan, the top twenty most intense ions with multiple charged ions above a threshold ion count of 5000 were selected for fragmentation. Fragment ion spectra were produced via collision-induced dissociation (CID) at normalized collision energy of 35% and they were acquired in the ion trap mass analyzer. AGC was set to 1 ⋅ 104, and an isolation window of 2.0 m/z, an activation time of 10 ms, and a maximum injection time of 100 ms were used. Data was acquired with Xcalibur software v2.2. Digested bovine serum albumin (New England Biolabs cat # P8108S) and was analyzed between each sample run to avoid sample carryover and to assure stability of the instrument. Finally QCloud (Chiva et al., 2018) was used to control instrument longitudinal performance during the project.

Data analysis

Acquired spectra were analyzed using the Proteome Discoverer software suite (v2.0, Thermo Fisher Scientific) and the Mascot search engine (v2.6, Matrix Science (Perkins et al., 1999)). Data were searched against a M. agalactiae strain 7784 database (76,678 entries) or M. pneumoniae M129 database (87,070 entries) plus a list of common contaminants and all the corresponding decoy entries (Perkins et al., 1999, Beer et al., 2017). For peptide identification, a precursor ion mass tolerance of 7 ppm was used for the MS1 level, trypsin was used as an enzyme, and up to three missed cleavage sites were allowed. The fragment ion mass tolerance was set to 0.5 Da for MS2 spectra. Oxidation of methionine and N-terminal protein acetylation were used as variable modifications, with carbamidomethylation on cysteine set as a fixed modification. False discovery rate (FDR) in peptide identification was set to a maximum of 5%. Peptide quantification data were retrieved from the “Precursor ion area detector” node from Proteome Discoverer (v2.0) using 2 ppm mass tolerance for the peptide extracted ion current (XIC). We then determined the area under the curve for each unique peptide and select the top three to determine the average area under the curve for each protein. The raw proteomics data were deposited in the PRIDE repository (Vizcaíno et al., 2016) with the dataset identifier PXD015800. The obtained dataset was normalized assuming equal total protein content for both species (using two biological replicates per species). Total protein content of sample 170718_TFLS_01_01 from M. pneumoniae was used as a reference for normalization (Tables S1 and S7). Once the area under the curve for each protein were normalized we determined the log2 of the area for each orthologous gene in the two species and we determined the difference in log2. A t test statistical analysis has been performed for each of the selected orthologous genes, two-tailed distribution and assuming unequal variances; later we corrected the obtained p values for multiple tests using Benjamini-Hochberg correction. For the specific comparison of individual orthologous genes p values were calculated assuming one-tailed distribution and assuming unequal variances. Orthology between M. pneumoniae M129, M. agalactiae 7784 and M. bovis PG45 was generated using the Microbial Genomes Database (MBGD) server considering default parameters and curated for duplicated using BlastP. We added up mass spectrometry areas of duplicated forms in M. agalactiae when the two copies were conserved respect the same protein in M. pneumoniae (Table S1). The average area under the curve of the three best-flying peptides was used to estimate the relative concentration of each protein. Data for both species were normalized assuming equal total protein content. As proteins highlighted with asterisk () in Figure 3 were not detected in the urea samples, the values obtained in SDS are shown after normalization, with an assumption of equal total protein content. The protein encoded by gene MPN637 in M. pneumoniae was not detected in these experiments but data was inferred from other M. pneumoniae proteomics datasets published in Miravet-Verde et al. (2019) with an average value of 25.75 log2. To represent protein abundance in Figure 3, all enzymes with an expression value of lower than 27 log2 were arbitrarily represented with same color code (green) to indicate “minimum.” Note that below this value, peptide detection becomes random, and protein concentrations cannot be accurately estimated. Thus, in Figure 3, protein expression levels range from 27 to 32.6 log2. The upper value corresponds to the maximum expression value obtained for the set of genes involved in sugar metabolism for the two species and is represented in magenta color (i.e., ldh, MAGA7784_RS02675).

Protein abundance variability analysis

In order to study if the protein abundance variability is reduced when considering proteins pertaining to a unique linear metabolic pathway, we extracted eight linear sub-pathways from the studied set of metabolic pathways (Table S1). Please note that for M. agalactiae the number of sub-pathways analyzed is seven because enzyme Pgi was included in linear sub-pathway one (genes involved in glycolipids) while in M. pneumoniae Pgi was grouped with Pfk, enzyme absent in M. agalactiae.

The selection was based on single entry and single exit genes (nodes with one entry edge and one exit edge) (Table S8). For both species separately, the coefficient of variation was calculated (CV, standard deviation corrected by the mean) and a background model of expected CVs by random sampling (1000 iterations with each of them a size equal to the number of proteins in the sub-pathway analyzed). The same process was repeated using raw quantification (natural) and using a log2 transformation (log) (Figures S2A and S2B for M. pneumoniae and Figures S2C and S2D for M. agalactiae). In parallel, we merged all sub-pathways together (independent for each species and alternatively with raw values and logarithmic values) and compared using Wilcoxon signed-rank tests the distribution of observed CVs to a distribution of average expected CVs by each linear sub-pathway (Table S8; Figure 4). P values obtained for M. pneumoniae for raw and log2 values are p value = 0.005 and p value = 0.012, respectively. P values obtained for M. agalactiae for raw and log2 values are p value = 0.045 and p value = 0.008, respectively

To unravel whether the similarity in protein abundances observed for enzymes involved in the same sub-pathway arises as a consequence of belonging the same transcriptional unit we showed operon distributions in M. pneumoniae from previously available literature (Güell et al., 2009, Junier et al., 2016). In the case of M. agalactiae, operon distribution information was collected from DOOR database, which predicts operon organization based on genomic features (Mao et al., 2009) using as reference organism the strain NC_013948.

The information of operon distribution for both strains is available in Table S9.

Gene essentiality

Transposon density values were different for both species, with a higher coverage obtained in the M. pneumoniae (Table S10 for the reanalyzed M. pneumoniae dataset) compared to M. agalactiae dataset (Montero-Blay et al., 2019). In both datasets, the culture medium used to perform the experiments was Hayflick supplemented with 0.5% glucose in the case of M. pneumoniae or 0.5% sodium pyruvate for M. agalactiae. The maximum values of transposon density observed for a gene in these species were 0.98 and 0.40 for M. pneumoniae and M. agalactiae, respectively. To represent these values in Figure 4, the range of transposon density values was normalized for each species independently. In Figure 4, colors are shown along a min–max scale after normalization for each of the species (from low transposon density in magenta, to high transposon density in white).

Quantification and Statistical Analysis

For the detection and analysis of proteomics samples we have used the Proteome Discoverer Software 2.0 and Mascot Search Engine 2.6 (default parameters). The exploration of orthologous genes for M. bovis, M. agalactiae and M. pneumoniae have been performed using software BlastP and the Microbial Genomes Database (MGDB, default parameters) as reference. The data analysis of the proteomics samples have been performed using general Python programming language and the ‘statsmodel’ package. For both species, the average (in log2) and standard deviation were calculated when signal was detected in both replicates. Then, a differential expression analysis was performed and fold-change was extracted. From this, a p-value extracted by two-tailed t-test for individual samples assuming unequal variances. Those p-values were corrected by Benjamini-Hochberg (FDR 5%) and -log10 of p-value was calculated, where highest values associate to the most different values (Table S1). For protein variability analysis, we used Python 3.6 and the packages ‘statsmodel’ for statistical analysis, ‘random’ for randomization of the sets, and ‘matplotlib’ for visualization. Script to reproduce the analysis of the variability between and within metabolic pathways using shotgun proteomics from M. pneumoniae and M. agalactiae can be accessed through this link: https://github.com/CRG-CNAG/MetabolicPathVariationCoeff. Data is presented in Table S8.

Acknowledgments

The proteomics analyses were performed in the CRG/UPF Proteomics Unit, which is part of the Proteored, PRB3, and is supported by grant PT 17/0019 of the PE I+D+i 2013-2016, funded by ISCIII and ERDF. We are especially grateful to Guadalupe Espadas-Garcia and Eduard Sabidó for technical and scientific guidance for proteomics. We thank V.A. Raker for manuscript editing. This project was financed by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program, under grant agreement nos. 634942 (MycoSynVac) and 670216 (MYCOCHASSIS). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme / Generalitat de Catalunya.

Author Contributions

A.M.-B. performed the experiments. A.M.-B. and S.M.-V. performed data analysis. L.S., M.L.-S., and C.P.-L. contributed with ideas and direct supervision of the project. All authors participated in evaluating results and discussions about the project. A.M.-B., C.P.-L., and L.S. wrote the paper. A.M.-B. and S.M.-V. prepared tables. A.M.-B. prepared figures. L.S., C.P.-L., S.M.-V., and M.L.-S. reviewed the manuscript. All authors read and approved the final manuscript.

Declaration of Interests

The authors declare no competing interests.

Published: June 2, 2020

Footnotes

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2020.107722.

Supplemental Information

Document S1. Figures S1–S3
mmc1.pdf (902.7KB, pdf)
Table S1. Gene Orthology and Mass Spectrometry Data Comparative for M. pneumoniae and M. agalactiae, Related to Figures 1 and 3

S1 includes a full orthology reference between the genomes of M. pneumoniae M129, M. agalactiae 7784 and M. bovis PG45 generated with MBGD. Table includes gene name (A), description (B), orthologous relation for M. pneumoniae M129 (C), M. agalactiae 7784 (D) and M. bovis PG45 (E). S2 Integration of gene orthology with mass spectrometry for M. pneumoniae M129 and M. agalactiae 7784. The subset of metabolic enzymes from orthology in S1 is included for M. pneumoniae, M. agalactiae and M. bovis. For M. agalactiae and M. bovis, exploration of missing genes in the orthology as well as orthologous in each species found in the other. When there is no orthologous gene we indicated it as Not Assigned (NA). Field (F) with a type of metabolites participating in the reaction catalyzed by each entry and (G) if additional metabolites participate. Columns H and I display a unique index to relate duplication clusters and the e-value between the gene in M. pneumoniae and each isoform in M. agalactiae. K-L includes protein areas for M. pneumoniae and N-O for M. agalactiae. Fields P and Q repeats the information from N-O except for the genes in M. agalactiae considered to be duplicated homologs sharing function (BlastP e value < 0.005). Not Assigned (NA) appears when no orthologous gene is found for that case, ND (standing for No detected) points out that protein has not been found by Mass spectrometry. Columns S-U include average, log2 (average) and st. deviation for the replicates only when signal can be found in both replicates; No calculated (NC) otherwise. This is repeated for M. agalactiae in V-X. Z-AD represents the differential expression analysis where only the cases labeled with 1 in Z are considered to extract a fold change (M. pneumoniae over M. agalactiae) in AA, a p value extracted by two-tailed t test for individual samples assuming unequal variances in AB, those p values corrected by Benjamini-Hochberg (FDR 5%) in column AC and finally, -log10 of p value in AD, where highest values associate to the most different values.

mmc2.xlsx (96.9KB, xlsx)
Table S2. Metabolites Identified for M. pneumoniae and M. bovis, Related to Figure 6

The sheet MPN metabolites identified, contains the list of metabolites experimentally identified for M. pneumoniae in the work of Maier et al. (2013) using GC-MS, LC-MS and NMR techniques. The sheet MBOV metabolites identified, contains the list of metabolites experimentally determined for M. gallisepticum and M. bovis in the work of Masukagami et al. (2017) using gas chromatography-mass spectrometry (GC/MS) and liquid chromatography-MS (LC/MS).

mmc3.xlsx (28.8KB, xlsx)
Table S3. Growth Curves Measurement for M. agalactiae Wild-Type (WT) and M. agalactiae Synthetic Strain, Related to Figure 2

S1 datasheet curves_MAGAWT contains protein measurements in μl/mL for M. agalactiae WT strain after 48 hours of growth in depleted medium. The depleted medium has been supplemented with different carbon sources as indicated. S2 datasheet HayflickvsDepleted_WT contains protein measurements in μl/ mL for M. agalactiae WT strain after 48 hours of growth either in complete Hayflick medium or a depleted version of this medium to show that even if no sugar is added in this version of the medium, there is growth of this bacterium. In addition, the number of division rounds in the depleted version is not affected if there is depletion of the medium versus the complete Hayflick medium. S3 datasheet Syntheti_MAGA growth curves contains protein measurements in μl/ mL for M. agalactiae synthetic strain after 48 hours of growth in depleted medium (transformed with MPN302 + MPN207 genes from M. pneumoniae). This version of the bacterium with restored glycolysis is capable to grow in presence of glucose. S4 datasheet Single mutants_growth curves contains protein measurements in μl/mL for M. agalactiae strain transformed with a single gene of M. pneumoniae (MPN302 or MPN207). Both genes are needed to restore glycolysis functionality.

mmc4.xlsx (30.3KB, xlsx)
Table S4. Glucose, Acetate, Lactate, and Ethanol Metabolic Measurements, Related to Figure 2

The measurement of the metabolites have been performed in alternative days and different batches. The medium utilized for each of the strain is Hayflick medium and supplemented with pyruvate for M. agalactiae (see STAR Methods) and glucose for M. pneumoniae. The basal levels of glucose, lactate, acetate and ethanol have been measured at initial time (t = 0 hours) and final point (t = 48 hours) of growth and then consumption or generation have been calculated. Number of replicates = 2.

mmc5.xlsx (17.5KB, xlsx)
Table S5. Description of Plasmids Used and Generated in This Work, Related to Figure 2
mmc6.xlsx (20.6KB, xlsx)
Table S6. Mass Spectrometry Analysis of M. pneumoniae WT, M. agalactiae WT, and M. agalactiae Synthetic Strain (MPN207 + MPN302) for Specific Protein Detection of PTS-Glucose-Specific Transporter (MPN207) and Phosphofructokinase Gene (MPN302) in M. agalactiae Synthetic Strain, Related to Figure 2
mmc7.xlsx (233.9KB, xlsx)
Table S7. Proteomics Data for M. pneumoniae WT and M. agalactiae WT, Related to Figure 3

Two experimental replicates have been performed in urea buffer and a single replicate using SDS lysis buffer. S1 UREAraw_data contains proteomics information for both species. S2 UREAunique_MPN contains proteomics information for M. pneumoniae for those proteins found strictly in both biological urea replicates. S3 UREAunique_MAGAL contains proteomics information for M. agalactiae for those proteins found strictly in both biological urea replicates. S4 SDS_MPN contains proteomics information for M. pneumoniae for a single replicate using SDS lysis buffer. S5 SDS_MAGA contains proteomics information for M. pneumoniae for a single replicate using SDS lysis buffer.

mmc8.xlsx (233.2KB, xlsx)
Table S8. Analysis of Proteomics Abundance Variation within and without Linear Pathways, Related to Figure 4

For M. pneumoniae (MPN) or M. agalactiae (MAGA) we present clusters of eight linear sub-pathways for M. pneumoniae and seven for M. agalactiae based on the selection of single-entry single-exit genes (nodes with one entry edge and one exit edge). For each of these sub-pathways we calculated the coefficient of variation (CV, standard deviation corrected by the mean) and a background model of expected CVs by random sampling). We repeated the same process using raw quantification values and using a log2 transformation.

mmc9.xlsx (618.5KB, xlsx)
Table S9. Transcriptional Units Organized in Operons for M. pneumoniae and M. agalactiae, Related to STAR Methods

The transcriptional units for M. pneumoniae were collected from Güell et al. (2009) and Junier et al. (2016). For M. agalactiae, the information was obtained from DOOR database using as reference organism the strain NC_013948.

mmc10.xlsx (97.5KB, xlsx)
Table S10. Transposon Density Values for M. pneumoniae, Related to Figure 5

The reference study is the study previously performed in M. pneumoniae (Lluch-Senar et al., 2015). Specifically, T4 dataset of M. pneumoniae was reanalyzed as described in Montero-Blay et al. (2019). Transposition events are considered to behave as random events resembling a Poisson process over large portions of the chromosome with a uniform density. Fully described in Montero-Blay et al. (2019).

mmc11.xlsx (70.6KB, xlsx)
Table S11. Measured Metabolites-Values in Serum from Human Samples in Different Studies Found in the Literature, Related to Figure 6

Culture medium used for Mycoplasmas (i.e., Hayflick medium) contains horse serum, which composition is similar than human serum.

mmc12.xlsx (13.2KB, xlsx)
Document S2. Article plus Supplemental Information
mmc13.pdf (6MB, pdf)

References

  1. Beer L.A., Liu P., Ky B., Barnhart K.T., Speicher D.W. Efficient quantitative comparisons of plasma proteomes using label-free analysis with MaxQuant. Methods Mol. Biol. 2017;1619:339–352. doi: 10.1007/978-1-4939-7057-5_23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Breuer M., Earnest T.M., Merryman C., Wise K.S., Sun L., Lynott M.R., Hutchison C.A., Smith H.O., Lapek J.D., Gonzalez D.J. Essential metabolism for a minimal cell. eLife. 2019;8:e36842. doi: 10.7554/eLife.36842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bürki S., Frey J., Pilo P. Virulence, persistence and dissemination of Mycoplasma bovis. Vet. Microbiol. 2015;179:15–22. doi: 10.1016/j.vetmic.2015.02.024. [DOI] [PubMed] [Google Scholar]
  4. Chiva C., Olivella R., Borràs E., Espadas G., Pastor O., Solé A., Sabidó E. QCloud: a cloud-based quality control system for mass spectrometry-based proteomics laboratories. PLoS ONE. 2018;13:e0189209. doi: 10.1371/journal.pone.0189209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gibson D.G., Young L., Chuang R.-Y., Venter J.C., Hutchison C.A., 3rd, Smith H.O. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods. 2009;6:343–345. doi: 10.1038/nmeth.1318. [DOI] [PubMed] [Google Scholar]
  6. Großhennig S., Schmidl S.R., Schmeisky G., Busse J., Stülke J. Implication of glycerol and phospholipid transporters in Mycoplasma pneumoniae growth and virulence. Infect. Immun. 2013;81:896–904. doi: 10.1128/IAI.01212-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Güell M., van Noort V., Yus E., Chen W.-H., Leigh-Bell J., Michalodimitrakis K., Yamada T., Arumugam M., Doerks T., Kühner S. Transcriptome complexity in a genome-reduced bacterium. Science. 2009;326:1268–1271. doi: 10.1126/science.1176951. [DOI] [PubMed] [Google Scholar]
  8. Himmelreich R., Hilbert H., Plagens H., Pirkl E., Li B.C., Herrmann R. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res. 1996;24:4420–4449. doi: 10.1093/nar/24.22.4420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hsu T.M., Welner D.H., Russ Z.N., Cervantes B., Prathuri R.L., Adams P.D., Dueber J.E. Employing a biochemical protecting group for a sustainable indigo dyeing strategy. Nat. Chem. Biol. 2018;14:256–261. doi: 10.1038/nchembio.2552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hunter J.D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 2007;9:90–95. [Google Scholar]
  11. Junier I., Unal E.B., Yus E., Lloréns-Rico V., Serrano L. Insights into the mechanisms of basal coordination of transcription using a genome-reduced bacterium. Cell Syst. 2016;2:391–401. doi: 10.1016/j.cels.2016.04.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kamminga T., Slagman S.-J., Bijlsma J.J.E., Martins Dos Santos V.A.P., Suarez-Diez M., Schaap P.J. Metabolic modeling of energy balances in Mycoplasma hyopneumoniae shows that pyruvate addition increases growth rate. Biotechnol. Bioeng. 2017;114:2339–2347. doi: 10.1002/bit.26347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kanehisa M., Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. doi: 10.1093/nar/28.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karp P.D., Weaver D., Latendresse M. How accurate is automated gap filling of metabolic models? BMC Syst. Biol. 2018;12:73. doi: 10.1186/s12918-018-0593-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kuznetsova E., Proudfoot M., Gonzalez C.F., Brown G., Omelchenko M.V., Borozan I., Carmel L., Wolf Y.I., Mori H., Savchenko A.V. Genome-wide analysis of substrate specificities of the Escherichia coli haloacid dehalogenase-like phosphatase family. J. Biol. Chem. 2006;281:36149–36161. doi: 10.1074/jbc.M605449200. [DOI] [PubMed] [Google Scholar]
  16. Lluch-Senar M., Delgado J., Chen W.-H., Lloréns-Rico V., O’Reilly F.J., Wodke J.A., Unal E.B., Yus E., Martínez S., Nichols R.J. Defining a minimal cell: essentiality of small ORFs and ncRNAs in a genome-reduced bacterium. Mol. Syst. Biol. 2015;11:780. doi: 10.15252/msb.20145558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Maier T., Marcos J., Wodke J.A.H., Paetzold B., Liebeke M., Gutiérrez-Gallego R., Serrano L. Large-scale metabolome analysis and quantitative integration with genomics and proteomics data in Mycoplasma pneumoniae. Mol. Biosyst. 2013;9:1743–1755. doi: 10.1039/c3mb70113a. [DOI] [PubMed] [Google Scholar]
  18. Mao F., Dam P., Chou J., Olman V., Xu Y. DOOR: a database for prokaryotic operons. Nucleic Acids Res. 2009;37:D459–D463. doi: 10.1093/nar/gkn757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Masukagami Y., De Souza D.P., Dayalan S., Bowen C., O’Callaghan S., Kouremenos K., Nijagal B., Tull D., Tivendale K.A., Markham P.F. Comparative metabolomics of Mycoplasma bovis and Mycoplasma gallisepticum reveals fundamental differences in active metabolic pathways and suggests novel gene annotations. mSystems. 2017;2 doi: 10.1128/mSystems.00055-17. e00055-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Miravet-Verde S., Ferrar T., Espadas-García G., Mazzolini R., Gharrab A., Sabido E., Serrano L., Lluch-Senar M. Unraveling the hidden universe of small proteins in bacterial genomes. Mol. Syst. Biol. 2019;15:e8290. doi: 10.15252/msb.20188290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Montero-Blay A., Miravet-Verde S., Lluch-Senar M., Piñero-Lambea C., Serrano L. SynMyco transposon: engineering transposon vectors for efficient transformation of minimal genomes. DNA Res. 2019;26:327–339. doi: 10.1093/dnares/dsz012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ochsner A.M., Christen M., Hemmerle L., Peyraud R., Christen B., Vorholt J.A. Transposon sequencing uncovers an essential regulatory function of phosphoribulokinase for methylotrophy. Curr. Biol. 2017;27:2579–2588.e6. doi: 10.1016/j.cub.2017.07.025. [DOI] [PubMed] [Google Scholar]
  23. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20:3551–3567. doi: 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  24. Pettersson B., Uhlén M., Johansson K.E. Phylogeny of some mycoplasmas from ruminants based on 16S rRNA sequences and definition of a new cluster within the hominis group. Int. J. Syst. Bacteriol. 1996;46:1093–1098. doi: 10.1099/00207713-46-4-1093. [DOI] [PubMed] [Google Scholar]
  25. Pollack J.D., Myers M.A., Dandekar T., Herrmann R. Suspected utility of enzymes with multiple activities in the small genome Mycoplasma species: the replacement of the missing “household” nucleoside diphosphate kinase gene and activity by glycolytic kinases. OMICS. 2002;6:247–258. doi: 10.1089/15362310260256909. [DOI] [PubMed] [Google Scholar]
  26. Ponce-de-León M., Apaolaza I., Valencia A., Planes F.J. On the inconsistent treatment of gene-protein-reaction rules in context-specific metabolic models. Bioinformatics. 2020;36:1986–1988. doi: 10.1093/bioinformatics/btz832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Qi J., Guo A., Cui P., Chen Y., Mustafa R., Ba X., Hu C., Bai Z., Chen X., Shi L., Chen H. Comparative geno-plasticity analysis of Mycoplasma bovis HB0801 (Chinese isolate) PLoS ONE. 2012;7:e38239. doi: 10.1371/journal.pone.0038239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rechnitzer H., Rottem S., Herrmann R. Reconstitution of an active arginine deiminase pathway in Mycoplasma pneumoniae M129. Infect. Immun. 2013;81:3742–3749. doi: 10.1128/IAI.00441-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rottem S. Interaction of mycoplasmas with host cells. Physiol. Rev. 2003;83:417–432. doi: 10.1152/physrev.00030.2002. [DOI] [PubMed] [Google Scholar]
  30. Seabold S., Perktold J. Statsmodels: econometric and statistical modeling with Python. In: van der Walt S., Millman J., editors. Proceedings of the 9th Python in Science Conference. Skipper Seabold; 2010. pp. 92–96. [Google Scholar]
  31. Vanyushkina A.A., Fisunov G.Y., Gorbachev A.Y., Kamashev D.E., Govorun V.M. Metabolomic analysis of three Mollicute species. PLoS ONE. 2014;9:e89312. doi: 10.1371/journal.pone.0089312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Virtanen P., Gommers R., Oliphant T.E., Haberland M., Reddy T., Cournapeau D., Burovski E., Peterson P., Weckesser W., Bright J., SciPy 1.0 Contributors SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods. 2020;17:261–272. doi: 10.1038/s41592-019-0686-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vizcaíno J.A., Csordas A., Del-Toro N., Dianes J.A., Griss J., Lavidas I., Mayer G., Perez-Riverol Y., Reisinger F., Ternent T. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44:11033. doi: 10.1093/nar/gkw880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Waites K.B., Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 2004;17:697–728. doi: 10.1128/CMR.17.4.697-728.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wiśniewski Quantitative Evaluation of Filter Aided Sample Preparation (FASP) and Multienzyme Digestion FASP Protocols. Anal Chem. 2016 doi: 10.1021/acs.analchem.6b00859. In press. [DOI] [PubMed] [Google Scholar]
  36. Wodke J.A.H., Puchałka J., Lluch-Senar M., Marcos J., Yus E., Godinho M., Gutiérrez-Gallego R., dos Santos V.A.P.M., Serrano L., Klipp E., Maier T. Dissecting the energy metabolism in Mycoplasma pneumoniae through genome-scale metabolic modeling. Mol. Syst. Biol. 2013;9:653. doi: 10.1038/msb.2013.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yang H., Krumholz E.W., Brutinel E.D., Palani N.P., Sadowsky M.J., Odlyzko A.M., Gralnick J.A., Libourel I.G.L. Genome-scale metabolic network validation of Shewanella oneidensis using transposon insertion frequency analysis. PLoS Comput. Biol. 2014;10:e1003848. doi: 10.1371/journal.pcbi.1003848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yus E., Maier T., Michalodimitrakis K., van Noort V., Yamada T., Chen W.H., Wodke J.A., Güell M., Martínez S., Bourgeois R. Impact of genome reduction on bacterial metabolism and its regulation. Science. 2009;326:1263–1268. doi: 10.1126/science.1177263. [DOI] [PubMed] [Google Scholar]
  39. Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019;363:eaat9931. doi: 10.1126/science.aat9931. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Document S1. Figures S1–S3
mmc1.pdf (902.7KB, pdf)
Table S1. Gene Orthology and Mass Spectrometry Data Comparative for M. pneumoniae and M. agalactiae, Related to Figures 1 and 3

S1 includes a full orthology reference between the genomes of M. pneumoniae M129, M. agalactiae 7784 and M. bovis PG45 generated with MBGD. Table includes gene name (A), description (B), orthologous relation for M. pneumoniae M129 (C), M. agalactiae 7784 (D) and M. bovis PG45 (E). S2 Integration of gene orthology with mass spectrometry for M. pneumoniae M129 and M. agalactiae 7784. The subset of metabolic enzymes from orthology in S1 is included for M. pneumoniae, M. agalactiae and M. bovis. For M. agalactiae and M. bovis, exploration of missing genes in the orthology as well as orthologous in each species found in the other. When there is no orthologous gene we indicated it as Not Assigned (NA). Field (F) with a type of metabolites participating in the reaction catalyzed by each entry and (G) if additional metabolites participate. Columns H and I display a unique index to relate duplication clusters and the e-value between the gene in M. pneumoniae and each isoform in M. agalactiae. K-L includes protein areas for M. pneumoniae and N-O for M. agalactiae. Fields P and Q repeats the information from N-O except for the genes in M. agalactiae considered to be duplicated homologs sharing function (BlastP e value < 0.005). Not Assigned (NA) appears when no orthologous gene is found for that case, ND (standing for No detected) points out that protein has not been found by Mass spectrometry. Columns S-U include average, log2 (average) and st. deviation for the replicates only when signal can be found in both replicates; No calculated (NC) otherwise. This is repeated for M. agalactiae in V-X. Z-AD represents the differential expression analysis where only the cases labeled with 1 in Z are considered to extract a fold change (M. pneumoniae over M. agalactiae) in AA, a p value extracted by two-tailed t test for individual samples assuming unequal variances in AB, those p values corrected by Benjamini-Hochberg (FDR 5%) in column AC and finally, -log10 of p value in AD, where highest values associate to the most different values.

mmc2.xlsx (96.9KB, xlsx)
Table S2. Metabolites Identified for M. pneumoniae and M. bovis, Related to Figure 6

The sheet MPN metabolites identified, contains the list of metabolites experimentally identified for M. pneumoniae in the work of Maier et al. (2013) using GC-MS, LC-MS and NMR techniques. The sheet MBOV metabolites identified, contains the list of metabolites experimentally determined for M. gallisepticum and M. bovis in the work of Masukagami et al. (2017) using gas chromatography-mass spectrometry (GC/MS) and liquid chromatography-MS (LC/MS).

mmc3.xlsx (28.8KB, xlsx)
Table S3. Growth Curves Measurement for M. agalactiae Wild-Type (WT) and M. agalactiae Synthetic Strain, Related to Figure 2

S1 datasheet curves_MAGAWT contains protein measurements in μl/mL for M. agalactiae WT strain after 48 hours of growth in depleted medium. The depleted medium has been supplemented with different carbon sources as indicated. S2 datasheet HayflickvsDepleted_WT contains protein measurements in μl/ mL for M. agalactiae WT strain after 48 hours of growth either in complete Hayflick medium or a depleted version of this medium to show that even if no sugar is added in this version of the medium, there is growth of this bacterium. In addition, the number of division rounds in the depleted version is not affected if there is depletion of the medium versus the complete Hayflick medium. S3 datasheet Syntheti_MAGA growth curves contains protein measurements in μl/ mL for M. agalactiae synthetic strain after 48 hours of growth in depleted medium (transformed with MPN302 + MPN207 genes from M. pneumoniae). This version of the bacterium with restored glycolysis is capable to grow in presence of glucose. S4 datasheet Single mutants_growth curves contains protein measurements in μl/mL for M. agalactiae strain transformed with a single gene of M. pneumoniae (MPN302 or MPN207). Both genes are needed to restore glycolysis functionality.

mmc4.xlsx (30.3KB, xlsx)
Table S4. Glucose, Acetate, Lactate, and Ethanol Metabolic Measurements, Related to Figure 2

The measurement of the metabolites have been performed in alternative days and different batches. The medium utilized for each of the strain is Hayflick medium and supplemented with pyruvate for M. agalactiae (see STAR Methods) and glucose for M. pneumoniae. The basal levels of glucose, lactate, acetate and ethanol have been measured at initial time (t = 0 hours) and final point (t = 48 hours) of growth and then consumption or generation have been calculated. Number of replicates = 2.

mmc5.xlsx (17.5KB, xlsx)
Table S5. Description of Plasmids Used and Generated in This Work, Related to Figure 2
mmc6.xlsx (20.6KB, xlsx)
Table S6. Mass Spectrometry Analysis of M. pneumoniae WT, M. agalactiae WT, and M. agalactiae Synthetic Strain (MPN207 + MPN302) for Specific Protein Detection of PTS-Glucose-Specific Transporter (MPN207) and Phosphofructokinase Gene (MPN302) in M. agalactiae Synthetic Strain, Related to Figure 2
mmc7.xlsx (233.9KB, xlsx)
Table S7. Proteomics Data for M. pneumoniae WT and M. agalactiae WT, Related to Figure 3

Two experimental replicates have been performed in urea buffer and a single replicate using SDS lysis buffer. S1 UREAraw_data contains proteomics information for both species. S2 UREAunique_MPN contains proteomics information for M. pneumoniae for those proteins found strictly in both biological urea replicates. S3 UREAunique_MAGAL contains proteomics information for M. agalactiae for those proteins found strictly in both biological urea replicates. S4 SDS_MPN contains proteomics information for M. pneumoniae for a single replicate using SDS lysis buffer. S5 SDS_MAGA contains proteomics information for M. pneumoniae for a single replicate using SDS lysis buffer.

mmc8.xlsx (233.2KB, xlsx)
Table S8. Analysis of Proteomics Abundance Variation within and without Linear Pathways, Related to Figure 4

For M. pneumoniae (MPN) or M. agalactiae (MAGA) we present clusters of eight linear sub-pathways for M. pneumoniae and seven for M. agalactiae based on the selection of single-entry single-exit genes (nodes with one entry edge and one exit edge). For each of these sub-pathways we calculated the coefficient of variation (CV, standard deviation corrected by the mean) and a background model of expected CVs by random sampling). We repeated the same process using raw quantification values and using a log2 transformation.

mmc9.xlsx (618.5KB, xlsx)
Table S9. Transcriptional Units Organized in Operons for M. pneumoniae and M. agalactiae, Related to STAR Methods

The transcriptional units for M. pneumoniae were collected from Güell et al. (2009) and Junier et al. (2016). For M. agalactiae, the information was obtained from DOOR database using as reference organism the strain NC_013948.

mmc10.xlsx (97.5KB, xlsx)
Table S10. Transposon Density Values for M. pneumoniae, Related to Figure 5

The reference study is the study previously performed in M. pneumoniae (Lluch-Senar et al., 2015). Specifically, T4 dataset of M. pneumoniae was reanalyzed as described in Montero-Blay et al. (2019). Transposition events are considered to behave as random events resembling a Poisson process over large portions of the chromosome with a uniform density. Fully described in Montero-Blay et al. (2019).

mmc11.xlsx (70.6KB, xlsx)
Table S11. Measured Metabolites-Values in Serum from Human Samples in Different Studies Found in the Literature, Related to Figure 6

Culture medium used for Mycoplasmas (i.e., Hayflick medium) contains horse serum, which composition is similar than human serum.

mmc12.xlsx (13.2KB, xlsx)
Document S2. Article plus Supplemental Information
mmc13.pdf (6MB, pdf)

Data Availability Statement

This study generated unique proteomics datasets. The datasets generated have been deposited in Pride Repository ID PXD015800. The code supporting this work is available in the following link https://github.com/CRG-CNAG/MetabolicPathVariationCoeff

RESOURCES